Which Form?

Best Form of GLP-1 Agonists

Short answer

Form verdict: Leaning against

Injectable GLP-1 drugs work better than the oral versions.

Based on what researchers say in public interviews on YouTube and on the studies Precis has read. Not medical advice. Always consult your healthcare provider before starting, stopping, or changing any supplement.

GLP-1 Agonists forms compared

One row per form claim. Each verdict is worked out from every counted mention: a researcher on tape or a study.

Claim Studies Researchers Verdict
Injectable GLP-1 drugs work better than the oral versions. 9 counted of 23 read 0 counted Leaning against

positive partly neutral negative Each researcher and each study counts once per claim, however often they come up.

Injectable GLP-1 drugs work better than the oral versions.

Leaning against

9 sources: 1 positive, 2 partly, 6 negative.

Researchers say

No researcher counted yet.

Studies show

1 positive, 2 partly, 6 negative

9 papers we read

14 more not counted · see why
Show the receipts from 9 sources
  1. Trial or observed group, J Endocrinol Invest, 2024, PMID 38683498 Study · positive

    After 6 months, both formulations significantly improved glycemic control and body weight, however injectable semaglutide showed a greater efficacy on A1c levels, weight loss, BMI and waist circumference reduction.

  2. Systematic review, Front Endocrinol (Lausanne), 2023, PMID 37701904 Study · partly

    According to the SUCRA results, the ranking of HbA1c reduction from highest to lowest was as follows: tirzepatide15mg>semaglutide1.0mg>PEX168-200μg>dulaglutide1.5mg>oral semaglutide14mg>liraglutide1.8mg>albiglutide30mg>weekly-exenatide2.0mg>daily-exenatide10μg>lixisenatide20μg>placebo.

  3. Systematic review, Diabetes Obes Metab, 2026, PMID 41992023 Study · partly

    Higher‐dose regimens (semaglutide 7.2 mg, orforglipron 36 mg and semaglutide 2.4 mg) demonstrated broader and more consistent improvements across cardiometabolic risk factors, whereas lower‐dose regimens showed more limited, domain‐specific effects.

  4. Other primary study, Diabetes Ther, 2019, PMID 31599391 Study · negative

    Orally administered semaglutide 14 mg QD as an add-on to 1-2 OADs is one of the most efficacious GLP-1 RAs for reducing HbA1c and body weight at 26 ± 4 weeks.

  5. Other primary study, Diabetes Ther, 2021, PMID 33723769 Study · negative

    Once-daily oral semaglutide 14 mg also offers the option of an oral treatment with similar or better efficacy and similar tolerability vs. most injectable GLP-1 RAs.

  6. Other primary study, Cell Rep Med, 2021, PMID 34622228 Study · negative

    Hence, interindividual variation in GLP-1R responsivity or route of administration are not major determinants of GLP-1RA effectiveness in the clinic.

  7. Other primary study, J Clin Med, 2024, PMID 39274378 Study · negative

    The oral formulation of semaglutide demonstrated equivalent effectiveness in glucose control and body weight management in patients with T2DM and CKD, even with a higher proportion of patients receiving low to medium doses.

  8. Controlled trial, Diabetes Obes Metab, 2026, PMID 42225300 Study · negative

    This ITC suggests that oral semaglutide 25 mg and s.c. semaglutide 2.4 mg offer comparable efficacy for weight management in adults with obesity.

  9. Trial or observed group, Int J Mol Sci, 2026, PMID 42278227 Study · negative

    Oral and subcutaneous semaglutide show comparable effectiveness in lowering HbA1c and BMI in a real-world setting.

More on GLP-1 Agonists